الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Suppression of tumorigenicity 2 (ST2) is a member of Interleukin-1 receptor family expressed mainly on T helper2 and mast cells. Interleukin-33 (IL-33) is the ligand for ST2 whose binding ultimately leads to production of the cytokines associated with T helper 2 response. ST2 exists in 2 main forms: the first is a membrane-bound full-length form (ST2L) which mediates IL-33 actions while the second is a soluble form (sST2) which is almost identical to the extracellular domain of the membrane-bound form and can be readily measured in peripheral blood It was also shown to attenuate atherosclerosis and to possess a protective effect in heart failure. However, IL-33/ST2 pathway promotes the pathogenesis of some clinical conditions like asthma, atopic dermatitis. The aim of the work: Patients and methods: Our study includes 70 children & 20 apparently healthy children their age ranged from 15 months to 180 months; they were recruited from Pediatric Intensive care unit, Pediatric Department, Menoufia University Hospital, during the period from January 2017 to August 2017.